La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Grifols a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Grifols..

Grifols (NASDAQ:GRFS) Azioni, Catena delle Opzioni

Grifols

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Grifols, S.A. - American Depositary Shares

Grifols SA

GRIFOLS ADR REP ONE NON VTG CL B ORD

WIIM

GRFS

Grifols shares are trading higher following a report suggesting Brookfield is seeking information on the company's related-party deals and that it is confident it can line up financing

News

Financing

Brookfield Is Said To Seek Info On Grifols Related-Party Deals; Said To Be Confident It Can Line Up Financing

Grifols shares are trading higher after the company announced it received FDA approval to treat surgical bleeding in pediatric patients with its fibrin sealant solution.

<ul>
<li>Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis</li>
<li>Grifols surgical bleeding management treatments form part of an increasingly robust portfolio of innovative therapeutics enhancing the health and well-being of patients &nbsp;</li>
</ul>
BARCELONA, Spain, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:<a href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding has received approval from the United States Food and Drug Administration (FDA) for pediatric patients.
The U.S. indication for children and adolescents extends the availability of FS, which is already approved for this patient segment in Europe, in addition to adults. During surgery Grifols FS promotes hemostasis and tissue sealing, resulting in reduced blood loss and potentially fewer complications.
Grifols FS biosurgery treatment is commercialized as VISTASEAL&#x2122; in the U.S. and Canada, and VERASEAL&#x2122; in Europe and elsewhere. Both brands are marketed and distributed by Johnson &amp; Johnson MedTech, as part of a strategic collaboration between the two companies announced in 2019.
Grifols FS combines two plasma proteins, fibrinogen and thrombin, and is applied with Johnson &amp; Johnson MedTech's airless spray technology to rapidly form clots. The FS solution is now available in 18 countries.

Biotech

General

Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution

Success Could Lead To FDA Approval For One Of The First Treatments For Chemical Warfare Ocular Damage, Phase 2 Trial For Dry Eye Disease Planned For 2025

Grifols Partners With BARDA For Testing Ocular Immunoglobulin Eye Drops As Treatment For Sulfur Mustard-Induced Eye Injury

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs &nbsp;
GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals
SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LYus6vr6e9kkAq1UFdnEMG_rFiPgb3buMnD1EXp_OmcSohXze17gw6aPoLbrltGSuEs4Oj_YBED1OsQ6UqvuXoA04Rxz2r_79ReiInhcuExlX32QTGd56a2BjByK0lEV2Auzdzx-M99lVVQrUqndKj7GNY6lCKL-oJM-GlHGcFWg5kTjkN3KgKGyDst1XAKO">GigaGen Inc.</a>, a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of <a href="https://www.globenewswire.com/Tracker?data=xsHSTMVkJs06-0kEN0wfCEXi2BXZZz3aZPpT4p5W8XMG2hSTSIHgnvK74MzZpn-TkPKjm6mxkYHbFBWQt1hzfA==">Grifols</a>, announced today that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The award, valued at up to $135.2 million, is to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a second biothreat of interest to the agency that will be determined at a later time.

Contracts

GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Tuesday.
Shares of Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) fell in today's pre-market trading after the company announced a <a href="https://www.benzinga.com/news/24/09/40991747/snowflake-stock-dips-on-offering-after-hours-what-to-know">$2 billion private placement of senior convertible notes.</a>
Snowflake announced it intends to offer $1 billion aggregate principal amount of its convertible senior notes due 2027 and a $1 billion aggregate principal amount of its convertible senior notes due 2029.
Snowflake shares fell 3.3% to $109.56 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) shares tumbled 17.1% to $93.43 in pre-market trading after the company received an order from the U.S. District Court for the District of Nevada granting Aristocrat a preliminary injunction relating to L&amp;W&#8217;s Dragon Train game..</li>
<li>Hawaiian Electric Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HE#NASDAQ">HE</a>) shares fell 10.5% to $9.75 in pre-market trading. Hawaiian Electric Industries raised $500 million via secondary stock offering of 54 million shares at $9.25 per share.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) fell 5.8% to $2.34 in pre-market trading. Uxin shares jumped 54% on Monday after the company reported a year-over-year increase in first-quarter sales results.</li>
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares declined 3.3% to $511.19 in pre-market trading.</li>
<li>Universal Stainless &amp; Alloy Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) fell 2.4% to $39.10 in pre-market trading.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 2.4% to $8.59 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARGX

SNOW

USAP

UXIN

Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Rumors

Brookfield In Talks With Sovereign Funds To Join Grifols Bid

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares soared 32.91%. The company announced that Lucid Financial Services has added leasing to its range of <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener">financing options in Canada</a>. Fed Chair Powell&#8217;s comments about the economy and interest rate cuts also improved the sentiment.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock rose 32.04% after it reported second-<a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">quarter financial results</a>.</li>
<li>PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) shares escalated 22.67% after the company announced FDA 510(k) clearance of <a href="https://www.benzinga.com//node/40481411" target="_blank" rel="noreferrer noopener">its HYDROS Robotic system</a>.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares were up 20.02%.</li>
<li>Evolent Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock upped 19.98% following a report suggesting <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener">the company is exploring a sale</a>.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares jumped 19.50% following a report suggesting that Brookfield Asset Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) is seeking debt financing to acquire the company.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) stock increased 19.33%.</li>
<li>Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) stock escalated 16.60% after it reported better-than-expected second-quarter <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener">results and raised its FY24 EPS outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543876/zoom-video-microstrategy-and-target-were-among-top-11-large-cap-gainers-last-week-aug-18-aug-24-ar" target="_blank" rel="noreferrer noopener">Zoom Video, MicroStrategy And Target Were Among Top 11 Large Cap Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543907/snowflake-jd-com-and-temu-parent-pdd-are-among-top-8-large-cap-losers-last-week-aug-18-aug-24-are-" target="_blank" rel="noreferrer noopener">Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Mid Cap

CRDO

LCID

NUVL

PRCT

Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday.
Shares of Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) rose sharply during Thursday's session following <a href="https://www.benzinga.com/news/earnings/24/08/40495102/zoom-video-reports-better-than-expected-q2-results-strong-forward-guidance-details">better-than-expected reported second-quarter financial results.</a>
Zoom reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.21 by 14.88%. Quarterly revenue of $1.16 billion also beat the consensus estimate and is a 2.09% increase from the same period last year.
Zoom Video shares jumped 12.2% to $67.62 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) shares jumped 27% to $4.27 after reporting better-than-expected second-quarter financial results.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 21% to $10.70 after the company announced a partnership with ePages.</li>
<li>Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) rose 16.7% to 14.99 after the company reported better-than-expected second-quarter financial results. Also, the company issued FY24 revenue guidance above estimates.</li>
<li>EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) gained 14.6% to $14.30 after the company reported better-than-expected second-quarter financial results.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) rose 11.5% to $8.55.</li>
<li>Olaplex Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) rose 11.4% to $2.44.</li>
<li>Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) gained 11.4% to $19.53.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 10.2% to $14.89.</li>
<li>OSI Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) rose 8.6% to $157.00 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Lindblad Expeditions Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) gained 8.6% to $8.93.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) rose 8.5% to $2.18.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) rose 7% to $9.66.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 4.7% to $16.14.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40506247/ibm-is-doing-a-great-job-jim-cramer-says-but-dont-buy-this-real-estate-stock">IBM Is Doing A &#8216;Great Job,&#8217; Jim Cramer Says — But Don&#8217;t Buy This Real Estate Stock</a></li>
</ul>

Intraday Update

CLMT

LIND

MNSO

OLPX

OPEN

OPRA

OSIS

PTON

RDFN

RZLV

Zoom Video Posts Strong Q2 Results, Joins Peloton Interactive, Opera And Other Big Stocks Moving Higher On Thursday

Grifols shares are trading higher after reports that Brookfield is seeking debt financing to acquire the company.

Brookfield Reportedly In Talks With Banks Including UBS And Bank Of America To Fund Grifols Takeover Bid

Brookfield Asset Management is reportedly seeking 9.5 billion euros ($10.6 billion) in debt financing for a potential take-private deal for Grifols SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>), a Spanish <a href="https://www.benzinga.com/general/health-care">pharmaceutical company.</a>
In a July regulatory filing, Grifols said that Brookfield Capital has confirmed that it has engaged in preliminary discussions with Grifols&#8217;s key shareholders regarding a potential joint offer to delist the company&#8217;s shares from the Spanish stock <a href="https://www.benzinga.com/general/biotech/24/07/39669365/beleaguered-spanish-drug-firm-grifols-stock-jumps-on-monday-heres-why" target="_blank" rel="noreferrer noopener">exchanges and NASDAQ</a>.
The investment firm has approached banks to secure funding to refinance Grifols&#8217; existing debt, which includes loans and high-yield bonds.
The move could result in significant financial restructuring, with participating banks committing to the initial financing before distributing it to investors.
The Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-08-21/brookfield-seeks-close-to-10-billion-debt-for-grifols-takeover?srnd=homepage-Europe" rel="noreferrer noopener">report</a> notes that the deal could be critical for Grifols, as it might trigger a clause that allows bondholders to demand repayment at a premium—significantly higher than current trading levels for some of its bonds.
The prospect of the acquisition led to a notable market response, with Grifols&#8217; 2028 bonds gaining over 6 cents to nearly 94 cents on the euro and the company&#8217;s shares rising by as much as 6.4% in Madrid.
The report notes that if the deal is finalized, it marks one of the largest takeovers of a publicly traded European company since 2022.
However, Brookfield&#8217;s ability to increase Grifols&#8217; debt is limited, given that the company has been scrutinized for its leverage levels.
Three agencies downgraded Grifols&#8217; credit rating this year, culminating in Moody&#8217;s Ratings <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37717622/grifols-gets-downgraded-fitch-s-p-flag-cash-flow-concerns-at-pharma-company" rel="noreferrer noopener">discontinuing coverage in July</a>.
In March, a new&nbsp;report by Gotham City Research questioned the company&#8217;s &#8220;transparency, integrity <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37517028/spanish-healthcare-firm-grifols-hit-with-new-gotham-citys-short-report-faces-questions-regarding-" rel="noreferrer noopener">and ethical conduct</a>.&#8221;
As per its February SEC <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1438569/000110465924025280/tm246711d1_6k.htm" rel="noreferrer noopener">filing</a>, Grifols had previously denied Gotham City&#8217;s accusations, saying it had already replied to all of the questions raised in the latter&#8217;s reports.
In January, the European Central Bank initiated inquiries into several lenders, urging them to disclose their exposure to&nbsp;Grifols&nbsp;and its affiliated entities following Gotham City Research&#8217;s accusations <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36675593/spanish-healthcare-firm-grifols-reputational-damage-and-debt-woes-european-central-bank-probes-le" rel="noreferrer noopener">of financial manipulation</a>.&nbsp;
Price Action: GRFS stock is up 10.2% at $7.92 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40484046/macys-q2-earnings-revenue-miss-points-to-challenging-environment-cuts-2024-forecast" target="_blank" rel="noreferrer noopener">Macy&#8217;s Q2 Earnings: Revenue Miss, Points To &#8216;Challenging&#8217; Environment, Cuts 2024 Forecast</a>.</li>
</ul>
Photo: Shutterstock

Health Care

Brookfield Negotiates Over $10B In Debt Financing For Acquisition Of Spanish Pharma Giant Grifols

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024
Containing more than 1,000 fully human recombinant anti-HBV antibodies, GIGA-2339 reproduces the human body's natural immune response
GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals
SAN CARLOS, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=iDGUPDDlHYtTOJbjoG8uFqxk646ASiqUJn2t_fFBuUjR37u_0tPhsugtRvNWSzceXG1bzwH0np-wYiUHDkzXr5MDlE1siWMvqitvz9XxVVmtiBVOCohO6fEsK8PLSr7KKNiDwUa-keJWQB_-tbpNu50li2ZB2i_Es5ikCaXxNQPyBUE09WkmHsUfYr0bsh94">GigaGen Inc.</a>, a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of <a href="https://www.globenewswire.com/Tracker?data=tN9swu9LAmdftJQuKrzEZUuj47NJRd0UmOhHjX8aNkmQbG6v7jmhtDmXKqAOIQ5wmw9IhwNFezhc_MM_N1TDGw==">Grifols</a>, announced today that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 trial to evaluate the company's first recombinant polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339.

Grifols' GigaGen Receives FDA Clearance Of IND Application For Phase 1 Trial Of Recombinant Polyclonal For HBV Treatment, GIGA-2339

<a href="https://www.bloomberg.com/news/articles/2024-07-30/grifols-new-auditor-finds-non-cash-accounting-discrepancy-linked-to-china-stake">https://www.bloomberg.com/news/articles/2024-07-30/grifols-new-auditor-finds-non-cash-accounting-discrepancy-linked-to-china-stake</a>
Spain's <a href="https://www.bloomberg.com/quote/GRF:SM">Grifols SA</a> is set to report an unexpected accounting adjustment related to its stake in <a href="https://www.bloomberg.com/quote/002252:CH">Shanghai RAAS</a>, according to a person familiar with the matter.
The company recorded €400 million ($433 million) more than it should have for the value of an asset owned by the Chinese firm, the person said, asking not to be named discussing private information. The adjustment, set to be announced as soon as Tuesday, will not affect Grifols' profit and loss statement, the person said.

Global

"Grifols' New Auditor Discovers Non-Cash Accounting Discrepancy Linked To China Stake; Spanish Company To Report Adjustment Related To China Stake; Discrepancy In Reserves Accounting Found By Auditor Deloitte" - Bloomberg News

FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients

Grifols Board Votes To Grant Brookfield Access To Information For Potential Takeover Bid; Establishes Independent Committee To Monitor Transaction Progress And Present Proposals To Board

Shares of Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) fell sharply <a href="https://www.benzinga.com/quote/ARHS/analyst-ratings">during Monday's session</a>.
Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16.
Arhaus shares dipped 7.9% to $14.55 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Morphic Holding, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) climbed 71% to $6.97 after jumping around 50% on Friday.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced AI tools to manage its lead generation platform.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares climbed 47% to $2.1928 after gaining 8% on Friday.</li>
<li>Hywin Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYW#NASDAQ">HYW</a>) gained 39.5% to $0.4352.</li>
<li>Shapeways Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) climbed 39% to $0.2918 after dipping 22% on Friday.</li>
<li>Myomo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYO#NYSE">MYO</a>) gained 32% to $3.80 after the company issued preliminary second-quarter revenue guidance above estimates.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) shares rose 31% to $0.3129 after jumping over 38% on Friday.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) climbed 31% to $0.7660 after the company closed a $2.5 million secured loan financing from an institutional investor, enabling the final payment of its litigation settlement.</li>
<li>LL Flooring Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LL#NYSE">LL</a>) surged 20.4% to $0.6789.</li>
<li>Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) rose 18.5% to $10.65.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) gained 17.2% to $8.24 after Brookfield confirmed it held exploratory discussions with certain shareholders of the company in relation to a potential joint offer for Grifols&#8217; shares.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) gained 17.2% to $14.13 after the company announced it received the Breakthrough Device Designation from the FDA for its Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) climbed 16% to $1.23. Newegg Commerce said the Presale for its tenth annual FantasTech Sales event is now live.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) rose 16% to $0.4164 after the company signed a reseller agreement with Survey Equipment Services focused on the provision of OPT&#8217;s unmanned surface vehicles in the US.</li>
<li>Mainz Biomed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) gained 16% to $0.45.</li>
<li>R1 RCM Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCM#NASDAQ">RCM</a>) shares climbed 14.2% to $12.52.</li>
<li>Acelyrin, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) gained 13.6% to $4.60.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) shares gained 12.3% to $31.89 after surging 20% on Friday.</li>
<li>IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) shares gained 12.1% to $38.41 after the company announced interim Phase 2 monotherapy expansion data for IDE397 in MTAP-deletion urothelial and lung cancer. Additionally, Mizuho initiated coverage on the stock with an Outperform rating.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) rose 11.3% to $27.88 after B of A Securities upgraded the stock from Underperform to Neutral.</li>
<li>Corning Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) gained 9.4% to $42.05 after the company increased its second-quarter core sales guidance.</li>
<li>Dynatronics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) shares rose 8.6% to $0.2310 after declining around 8% on Friday.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) rose 4.6% to $21.41. Paramount Global and Skydance Media inked a definitive agreement to create a new entity, "New Paramount," in a $28 billion merger deal.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gained 3.8% to $33.26. Intel has bypassed Vietnam for a substantial investment project, citing insufficient investment incentives.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>HilleVax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) shares dipped 86.7% to $1.87 after the company announced the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants.</li>
<li>Adamas One Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JEWL#NASDAQ">JEWL</a>) shares dipped 83% to $0.3360 after dipping over 20% on Friday.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 66.4% to $0.7303 after dipping 24% on Friday.</li>
<li>SYLA Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYT#NASDAQ">SYT</a>) fell 31.1% to $2.0950.</li>
<li>Chijet Motor Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) dipped 28.4% to $5.80.</li>
<li>Ryde Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NASDAQ">RYDE</a>) declined 22.8% to $6.33.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) fell 21% to $10.55.</li>
<li>Wetouch Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) fell 19.5% to $2.57. Wetouch Technologies announced a $15 million stock buyback program to repurchase common stock.</li>
<li>Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) declined 19.4% to $0.16</li>
<li>Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) shares fell 15.2% to $4.1050. Beneficient said it will release its fourth quarter financial results before the opening bell on Tuesday, July 9.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares fell 15.1% to $18.77.</li>
<li>Vivakor inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIVK#NASDAQ">VIVK</a>) shares fell 15% to $1.97.</li>
<li>Inventiva S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NYSE">IVA</a>) shares fell 12% to $2.6050 after the company issued an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) dipped 11.3% to $1.77 after the company announced a partnership with Zhengzhou Airport Industry for the launch of a new used car superstore.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) fell 10.7% to $3.3099.</li>
<li>The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) dipped 10.6% to $43.37 after the company reported worse-than-expected quarterly financial results.</li>
<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares declined 7.2% to $0.2599 after jumping 60% on Friday.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) fell 7% to $0.2943.</li>
<li>Zuora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZUO#NYSE">ZUO</a>) fell 5.6% to $9.02. Craig-Hallum analyst Chad Bennett downgraded Zuora from Buy to Hold and lowered the price target from $12 to $10.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/07/39667298/this-dominos-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">This Domino&#8217;s Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a>

ARHS

BENF

CJET

CLDI

CLEU

DYNT

HLVX

IDYA

INTC

IONM

JEWL

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MORF

MYNZ

NEGG

NKLA

OPTT

PARAA

PLSE

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RYDE

SEDG

SHPW

SIRI

SLRN

SVMH

VIVK

VRPX

WETH

ZAPP

Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session

In a regulatory filing, Grifols SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) said that Brookfield Capital has confirmed that it has engaged in preliminary discussions with Grifols&#8217;s key shareholders regarding a potential joint offer to delist the company&#8217;s shares from the Spanish stock exchanges and NASDAQ.
Brookfield and the shareholders have <a target="_blank" href="https://www.cnmv.es/webservices/verdocumento/ver?t=%7be3178c56-707c-47af-8d9d-623a921c67e2%7d" rel="noreferrer noopener">signed</a> an exclusivity agreement to explore this possibility further and requested access to certain company information to conduct due diligence.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36675593/spanish-healthcare-firm-grifols-reputational-damage-and-debt-woes-european-central-bank-probes-le" rel="noreferrer noopener">Spanish Healthcare Firm Grifols&#8217; Reputational Damage and Debt Woes: European Central Bank Probes Lenders</a>.
According to the information provided to the Board of Directors, Brookfield, and the Grifols family shareholders have <a target="_blank" href="https://www.cnmv.es/webservices/verdocumento/ver?t=%7b23e05d73-1ba6-444a-8f97-59f8768ba300%7d" rel="noreferrer noopener">agreed</a> to evaluate a possible joint takeover bid to acquire Grifols.
The Board of Directors held an extraordinary meeting to allow access to certain company information to carry out a due diligence process regarding the intent of the transaction, in case The board goes through, would be delisting the company.
Reuters noted that the founding family members own a 30% stake in Grifols.
In a regulatory filing, the Comisión Nacional del Mercado de Valores <a target="_blank" href="https://www.cnmv.es/webservices/verdocumento/ver?t=%7b2f97ca15-3084-4b70-98ae-c81537dd030b%7d" rel="noreferrer noopener">made</a> the following decision: &#8220;Effective from 12:00 PM today, the precautionary suspension of Grifols has been lifted, applying to shares and related securities on the Stock Exchanges and Sistema de Interconexión Bursátil, Derivative contracts on these shares on MEFF Sociedad Rectora del Mercado de Productos Derivados, S.A.U., and Fixed Income Instruments issued on the CAPI OTF.
Earlier, CNMV <a target="_blank" href="https://www.cnmv.es/webservices/verdocumento/ver?t=%7b2f97ca15-3084-4b70-98ae-c81537dd030b%7d" rel="noreferrer noopener">agreed</a> to suspend the trading of Grifols shares.
The suspension was lifted because sufficient information about the circumstances leading to the suspension has been made public to market operators and the CNMV.&#8221;
Citing business newspaper Cinco Dias, Reuters noted that the founding family aims to gain access to the company&#8217;s books to make a final offer in the coming weeks.
Reuters highlighted that the deal could be worth around 5.5 billion euros ($5.96 billion).
In March, Gotham City Research released a new report on Grifols questioning the company&#8217;s &#8220;transparency, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37517028/spanish-healthcare-firm-grifols-hit-with-new-gotham-citys-short-report-faces-questions-regarding-" rel="noreferrer noopener">integrity and ethical conduct</a>.&#8221;
Recently, &nbsp;Grifols appointed&nbsp;Rahul Srinivasan as the new Chief Financial Officer, <a target="_blank" href="https://www.grifols.com/en/view-news/-/news/grifols-appoints-rahul-srinivasan-as-new-chief-financial-officer" rel="noreferrer noopener">effective September 16</a>.
Price Action: GRFS shares are up 20.90% at $8.51 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/03/37717622/grifols-gets-downgraded-fitch-s-p-flag-cash-flow-concerns-at-pharma-company" target="_blank" rel="noreferrer noopener">Grifols Gets Downgraded: Fitch, S&amp;P Flag Cash Flow Concerns At Pharma Company</a>.</li>
</ul>
Photo via Wikimedia Commons

Beleaguered Spanish Drug Firm Grifols Stock Jumps On Monday - Here's Why

U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday.
Shares of Corning Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) rose sharply during Monday's session after the company increased its second-quarter <a href="https://www.benzinga.com/markets/equities/24/07/39665128/why-apples-glass-supplier-corning-shares-are-jumping-premarket-today">core sales guidance</a>.
The company said it now projects core sales to be approximately $3.6 billion (vs. consensus of $3.41 billion), an increase from the previous guidance of $3.4 billion. Core EPS is expected to reach the high end of, or slightly exceed, the management's guided range of $0.42 to $0.46 (vs. estimate of $0.45).
Corning shares jumped 9.4% to $42.05 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Morphic Holding, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>) shares gained 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash.</li>
<li>Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) shares climbed 18.5% to $10.65.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) rose 17.2% to $8.24 after Brookfield confirmed it held exploratory discussions with certain shareholders of the company in relation to a potential joint offer for Grifols&#8217; shares.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) jumped 17.2% to $14.13 after the company announced it received the Breakthrough Device Designation from the FDA for its Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) gained 16% to $1.23. Newegg Commerce said the Presale for its tenth annual FantasTech Sales event is now live.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) shares rose 12.3% to $31.89 after surging 20% on Friday.</li>
<li>IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) shares climbed 12.1% to $38.41 after the company announced interim Phase 2 monotherapy expansion data for IDE397 in MTAP-deletion urothelial and lung cancer. Additionally, Mizuho initiated coverage on the stock with an Outperform rating.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 12% to $3.55.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) gained 11.3% to $27.88 after B of A Securities upgraded the stock from Underperform to Neutral.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) rose 11% to $1.08.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 6.5% to $902.31.</li>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) gained 6.2% to $17.61.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) climbed 4.7% to $3.06 after the company reported second-quarter production and deliveries.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) rose 4.7% to $42.33.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) climbed 4.6% to $21.41. Paramount Global and Skydance Media inked a definitive agreement to create a new entity, "New Paramount," in a $28 billion merger deal.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) rose 3.8% to $33.26. Intel has bypassed Vietnam for a substantial investment project, citing insufficient investment incentives.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) gained 3.8% to $15.35.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39665755/wall-streets-most-accurate-analysts-say-buy-these-3-utilities-stocks-delivering-high-div">Wall Street&#8217;s Most Accurate Analysts Say Buy These 3 Utilities Stocks Delivering High-Dividend Yields</a>

ABSI

FLNC

PSNY

RIVN

SMCI

TNDM

Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday

Brookfield asks for more time to weigh potential Grifols deal - report

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular surface...

Grifols partners with BARDA for PoC testing of ocular immunoglobulin

Grifols falls on report Brookfield delays offer on funding issues

Berenberg lowered the firm's price target on Grifols (GRFS) to EUR 15.50 from EUR 15.60 and keeps a Buy rating on the shares. Published first on Th...

Grifols price target lowered to EUR 15.50 from EUR 15.60 at Berenberg

Brookfield Asset Management (BAM) is awaiting information from Grifols (GRFS) about related-party transactions as it seeks to complete its due dili...

Brookfield awaiting information for potential Grifols bid, Bloomberg says

12:02 EST Brookfield still pursuing Grifols (GRFS) deal, Bloomberg reports Published first on TheFly – the ultimate source for real-time, market-mo...

Brookfield still pursuing Grifols deal, Bloomberg reports

Grifols gains after report Brookfield still pursuing possible takeover

Rahul Srinivasan, Chief Financial Officer, said "This record-breaking quarter stands as a testament to the passion and commitment of our entire tea...

Grifols reaffirms FY24 guidance

Revenue increased by 12.4% in constant currencty to EUR 1.793B for the third quarter and adjusted EBITDA in Q3 grew by 26.7% cc to EUR 462M. Nacho ...

Grifols reports Q3 adjusted EBITDA of EUR 462M, up 26.7% in constant currency

GIFLF

GIKLY

Press Releases

GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors

Grifols' Biotest receives FDA approval for innovative Yimmugo® immunoglobulin  to treat primary immunodeficiencies

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

Grifols' Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

Grifols S.A. (GRFS) Admits Improper Accounting, Announces Restatements, Shares Decline Again – Hagens Berman

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Comments

Grifols

Grifols (GRFS) Opzioni

Grifols (NASDAQ:GRFS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO